- Home
- SXC vs TRVI Comparison
SXC vs TRVI Comparison
Compare SXC & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SXC
- TRVI
- Stock Information
- Founded
- SXC 1960
- TRVI 2011
- Country
- SXC United States
- TRVI United States
- Employees
- SXC N/A
- TRVI N/A
- Industry
- SXC Steel/Iron Ore
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- SXC Industrials
- TRVI Health Care
- Exchange
- SXC Nasdaq
- TRVI Nasdaq
- Market Cap
- SXC 653.6M
- TRVI 725.7M
- IPO Year
- SXC N/A
- TRVI 2019
- Fundamental
- Price
- SXC $7.72
- TRVI $8.21
- Analyst Decision
- SXC Strong Buy
- TRVI Strong Buy
- Analyst Count
- SXC 1
- TRVI 9
- Target Price
- SXC $13.00
- TRVI $20.72
- AVG Volume (30 Days)
- SXC 938.3K
- TRVI 2.8M
- Earning Date
- SXC 10-30-2025
- TRVI 11-05-2025
- Dividend Yield
- SXC 6.18%
- TRVI N/A
- EPS Growth
- SXC 15.74
- TRVI N/A
- EPS
- SXC 0.85
- TRVI N/A
- Revenue
- SXC $1,846,200,000.00
- TRVI N/A
- Revenue This Year
- SXC N/A
- TRVI N/A
- Revenue Next Year
- SXC N/A
- TRVI N/A
- P/E Ratio
- SXC $9.15
- TRVI N/A
- Revenue Growth
- SXC N/A
- TRVI N/A
- 52 Week Low
- SXC $7.18
- TRVI $2.36
- 52 Week High
- SXC $12.82
- TRVI $9.83
- Technical
- Relative Strength Index (RSI)
- SXC 51.13
- TRVI 59.58
- Support Level
- SXC $7.53
- TRVI $6.93
- Resistance Level
- SXC $7.83
- TRVI $9.92
- Average True Range (ATR)
- SXC 0.19
- TRVI 0.71
- MACD
- SXC 0.04
- TRVI 0.19
- Stochastic Oscillator
- SXC 72.22
- TRVI 57.86
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. Its coke is primarily used as a principal raw material in the blast furnace steelmaking process as well as in the foundry production of casted iron. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers. The majority of revenue is derived from the Domestic Coke segment.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.